Key facts
- KKR will acquire Integer Holdings in an all-cash deal valued at $5.7 billion.
- KKR will offer $127 per share for Integer Holdings.
- The offer represents a premium to Integer's closing share price and 30-day VWAP.
- Integer Holdings is a contract developer and manufacturer of medical devices and components.
- The transaction is expected to close by the end of the year.
Private equity firm KKR has entered into a definitive agreement to acquire Integer Holdings Corporation, a global medical device contract development and manufacturing organization (CDMO), in an all-cash transaction valued at approximately $5.7 billion.
Under the terms of the agreement, Integer stockholders will receive $127 per share. This offer represents a premium of approximately 51.8% to Integer's closing share price on April 29, 2026, and 28.8% to the 30-day volume-weighted average price (VWAP) as of July 31, 2026. Integer Holdings, based in Plano, Texas, manufactures critical components and devices used in various medical technologies, including pacemakers, defibrillators, and neurostimulation implants.
Payman Khales, President and CEO of Integer, stated that the transaction recognizes the strength of Integer's business and provides stockholders with immediate and certain value, positioning KKR as the right strategic partner for the company's next chapter. Max Lin, Partner at KKR, highlighted Integer's differentiated capabilities, track record for quality, and presence in attractive end-markets, expressing excitement about advancing Integer's growth and innovation.
KKR intends to establish a broad-based employee ownership and engagement program at Integer following the close of the transaction. The definitive agreement follows a comprehensive strategic review initiated by Integer's Board of Directors. The transaction is expected to close by the end of the year, subject to customary closing conditions, including approval by Integer stockholders and receipt of required regulatory approvals.